Jörg Cammenga

4.0k total citations
65 papers, 2.4k citations indexed

About

Jörg Cammenga is a scholar working on Hematology, Molecular Biology and Cancer Research. According to data from OpenAlex, Jörg Cammenga has authored 65 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Hematology, 31 papers in Molecular Biology and 14 papers in Cancer Research. Recurrent topics in Jörg Cammenga's work include Acute Myeloid Leukemia Research (39 papers), Hematopoietic Stem Cell Transplantation (18 papers) and Histone Deacetylase Inhibitors Research (9 papers). Jörg Cammenga is often cited by papers focused on Acute Myeloid Leukemia Research (39 papers), Hematopoietic Stem Cell Transplantation (18 papers) and Histone Deacetylase Inhibitors Research (9 papers). Jörg Cammenga collaborates with scholars based in Sweden, United States and Germany. Jörg Cammenga's co-authors include Stephen D. Nimer, Matilda Rehn, James C. Mulloy, Zaal Kokaia, Olle Lindvall, Andreas Arvidsson, Pär Thored, James Wood, Francisco J. Berguido and David Bryder and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Blood.

In The Last Decade

Jörg Cammenga

64 papers receiving 2.3k citations

Peers

Jörg Cammenga

HEMAT

GENET

ONCOL

Isobel A. Scarisbrick United States

Persio Dello Sbarba Italy

Joachim R. Göthert Germany

Karen Keeshan United Kingdom

Kentaro Hosokawa Japan

Michael I. Dorrell United States

Edith Aguilar United States

Gus Khursigara United States

Mary Mohrin United States

William Eades United States

Isobel A. Scarisbrick United States

Jörg Cammenga

766 ×0.6

1.1k ×0.9

HEMAT

352 ×0.9

1.3k ×3.3

GENET

491 ×1.5

ONCOL

Citations per year, relative to Jörg Cammenga Jörg Cammenga (= 1×) peers Isobel A. Scarisbrick

Countries citing papers authored by Jörg Cammenga

Since Specialization

Citations

This map shows the geographic impact of Jörg Cammenga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jörg Cammenga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jörg Cammenga more than expected).

Fields of papers citing papers by Jörg Cammenga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jörg Cammenga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jörg Cammenga. The network helps show where Jörg Cammenga may publish in the future.

Co-authorship network of co-authors of Jörg Cammenga

This figure shows the co-authorship network connecting the top 25 collaborators of Jörg Cammenga. A scholar is included among the top collaborators of Jörg Cammenga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jörg Cammenga. Jörg Cammenga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Qinyu, Anna Rydström, Isabel Hidalgo, Jörg Cammenga, & A. Nilsson. (2025). Medium-dose irradiation impairs long-term hematopoietic stem cell functionality and hematopoietic resilience to cytotoxic stress. The International Journal of Biochemistry & Cell Biology. 186. 106814–106814.

Cammenga, Jörg. (2024). Of gains and losses: SAMD9/SAMD9L and monosomy 7 in myelodysplastic syndrome. Experimental Hematology. 134. 104217–104217. 4 indexed citations

Baliakas, Panagiotis, Bianca Tesi, Jörg Cammenga, et al.. (2024). How to manage patients with germline DDX41 variants: Recommendations from the Nordic working group on germline predisposition for myeloid neoplasms. HemaSphere. 8(8). e145–e145. 3 indexed citations

Nilsson, A., Hongxu Xian, Shabnam Shalapour, Jörg Cammenga, & Michael Karin. (2023). IRF1 regulates self-renewal and stress responsiveness to support hematopoietic stem cell maintenance. Science Advances. 9(43). eadg5391–eadg5391. 10 indexed citations

Ghosh, Somadri, Leal Oburoglu, Mats Ehinger, et al.. (2023). Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity. Blood Advances. 7(18). 5382–5395. 15 indexed citations

Vertemara, Jacopo, Claes Ladenvall, Anna Norberg, et al.. (2023). Novel pathological variants of NHP2 affect N-terminal domain flexibility, protein stability, H/ACA Ribonucleoprotein (RNP) complex formation and telomerase activity. Human Molecular Genetics. 32(19). 2901–2912. 2 indexed citations

Ugale, Amol, Tommaso De Marchi, Jenny Hansson, et al.. (2022). A somatic mutation in moesin drives progression into acute myeloid leukemia. Science Advances. 8(16). eabm9987–eabm9987. 2 indexed citations

Adolfsson, Jörgen, et al.. (2021). Multiplexed single‐cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells. Experimental Hematology and Oncology. 10(1). 7–7. 3 indexed citations

Baliakas, Panagiotis, Bianca Tesi, Ulla Wartiovaara‐Kautto, et al.. (2019). Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up. HemaSphere. 3(6). e321–e321. 53 indexed citations

10.

Velasco-Hernández, Talía, et al.. (2018). Hif-1α Deletion May Lead to Adverse Treatment Effect in a Mouse Model of MLL-AF9-Driven AML. Stem Cell Reports. 12(1). 112–121. 10 indexed citations

11.

Nagata, Yasunobu, Bartlomiej Przychodzen, Cassandra M. Hirsch, et al.. (2017). Germline SAMD9 and SAMD9L Alterations in Adult Myelodysplastic Syndromes. Blood. 130. 1670–1670. 3 indexed citations

12.

Velasco-Hernández, Talía, Jörg Cammenga, & David Bryder. (2017). Targeting hypoxia pathway in a model of acute myeloid leukemia. Experimental Hematology. 53. S61–S61. 1 indexed citations

13.

Velasco-Hernández, Talía, Petter Säwén, David Bryder, & Jörg Cammenga. (2016). Potential Pitfalls of the Mx1-Cre System: Implications for Experimental Modeling of Normal and Malignant Hematopoiesis. Stem Cell Reports. 7(1). 11–18. 47 indexed citations

14.

Reckzeh, Kristian, Oxana Bereshchenko, Adam J. Mead, et al.. (2012). Molecular and cellular effects of oncogene cooperation in a genetically accurate AML mouse model. Leukemia. 26(7). 1527–1536. 28 indexed citations

15.

Reckzeh, Kristian & Jörg Cammenga. (2010). Molecular mechanisms underlying deregulation of C/EBPα in acute myeloid leukemia. International Journal of Hematology. 91(4). 557–568. 25 indexed citations

16.

Quéré, Ronan, Ann Brun, Roman A. Zubarev, et al.. (2010). High levels of the adhesion molecule CD44 on leukemic cells generate acute myeloid leukemia relapse after withdrawal of the initial transforming event. Leukemia. 25(3). 515–526. 60 indexed citations

17.

Pietras, Alexander, Loen M. Hansford, A. Johnsson, et al.. (2009). HIF-2α maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. Proceedings of the National Academy of Sciences. 106(39). 16805–16810. 111 indexed citations

18.

Järås, Marcus, Helena Ågerstam, Carin Lassen, et al.. (2009). Expression of P190 and P210 BCR/ABL1 in normal human CD34+ cells induces similar gene expression profiles and results in a STAT5-dependent expansion of the erythroid lineage. Experimental Hematology. 37(3). 367–375. 11 indexed citations

19.

Niebuhr, Birte, et al.. (2007). Gatekeeper function of the RUNX1 transcription factor in acute leukemia. Blood Cells Molecules and Diseases. 40(2). 211–218. 31 indexed citations

20.

Cammenga, Jörg. (2005). Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML. Leukemia. 19(10). 1719–1728. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact